| 4:00–8:00 PM | Arrival and Registration | Foyer |
| 6:00–8:00 PM | Welcome Mixer | Foyer |
| 7:30–8:30 AM | Breakfast | Individual Hotel |
| 8:00–8:30 AM | Poster Setup | Suites 1-5 |
| 8:00–5:00 PM | Poster Viewing | Suites 1-5 |
| 8:30–9:30 AM | Welcome and Keynote Address | Great Ilanga |
| * Mike McCune, Gates Foundation |
| Thumbi Ndung'u, University of KwaZulu-Natal Combination Approaches for HIV Cure in Resource-Limited Settings |
| 9:30–11:45 AM | Biology of the Rebound Competent Reservoir I: The how, what, and why of the HIV reservoir | Great Ilanga |
| * Susana T. Valente, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology Session Chair |
| Kavidha Reddy, Africa Health Research Institute (AHRI) HIV-1 Reservoir Characteristics in Acutely Treated Adults and Children: Implications for HIV Cure Strategies |
| Ya-Chi Ho, Yale University Mechanisms of HIV Persistence In Tissues - Single Cell Multi-Omic And Spatial Transcriptomic Approaches |
| Sizun Jiang, Harvard Technological Advancements for High-Dimensional Spatial Analysis of Tissue Viral Rebound Using an NHP SIV model |
| Isabella Ferreira, Weill Cornell Medicine Short Talk: Propagation of Authentic HIV Reservoir Clones Reveals Functional Variability, Suggesting Diverse Mechanisms of Persistence |
| Alicer Andrew, Gladstone Institutes Short Talk: CXCR5-expressing HIV-specific CD8+ T Cells from Elite Controllers Exhibit Signs of Recent but Not Chronic Activation |
| 10:00–10:20 AM | Coffee Break | Foyer |
| 11:45–12:45 PM | Lunch | Suites 1-5 |
| 12:00–2:30 PM | Poster Session 1 | Suites 1-5 |
| 2:30–4:30 PM | Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions | Great Ilanga |
| * Nonhlanhla N Mkhize, National Institute for Communicable Diseases Session Chair |
| Helena Lamptey, Noguchi Memorial Institute for Medical Research, University of Ghana The Impact of Hepatitis B Co-infection on T-Cell Responses and Reservoir Size in Virologically Suppressed HIV Patients on Antiretroviral Therapy in Ghana |
| Eric Arts, Western University Packing the HLP Latency Reversal Agent with a Better Punch and Increasing Coverage as an HIV-1 Cure for all People Living with HIV |
| Christine Goffinet, Liverpool School of Tropical Medicine Type I Interferons Sensitise HIV-1-reactivating T-cells for NK cell-mediated Elimination Despite HDACi-imposed Dysregulation of Innate Immunity |
| Elena Martinelli, Northwestern University Metabolic Reprogramming of CD4+ T Cells by TGF-β Inhibition and ART Shapes the SIV Reservoir |
| Miguel Angel Marin Lopez, Africa Health Research Institute Distinct CD4 Tissue-resident Memory (TRM) Depletion and CD8 TRM Function between the Small and Large Intestine Indicate Region-specific Mechanisms for Gut Pathology in People with HIV (PWH) |
| Thuong D Nguyen, IRSICAIXA, Barcelona ChAdOx1/MVA-based HTI Vaccination Induces Strong, Broad de-novo CD8 T Cell Responses of Elevated Functional Avidity |
| 4:30–5:00 PM | Coffee Available | Foyer |
| 5:00–7:00 PM | Biology of the Rebound Competent Reservoir II: Host Factors that influence HIV persistence | Great Ilanga |
| * Glenda E Gray, HVTN / IDORI Session Chair |
| Melanie M Ott, Gladstone Institutes Silencing the Transcriptionally Active HIV Reservoir |
| Sharon R Lewin, University of Melbourne The Role of mRNA Therapeutics to Reverse HIV Latency |
| Caroline T. Tiemessen, National Institute for Communicable Diseases Harnessing Immunogenetics in the Pursuit of Pediatric HIV Remission |
| Ujjwal Neogi, Karolinska Institutet Mitochondrial Dysregulation and HIV Latency: A Metabolic Pathway to a Functional Cure? |
| 7:00–8:00 PM | On Own for Dinner |
| 7:30–8:30 AM | Breakfast | Individual Hotel |
| 8:00–8:30 AM | Poster Setup | Suites 1-5 |
| 8:00–5:00 PM | Poster Viewing | Suites 1-5 |
| 8:30–11:30 AM | Sizing Up the Reservoir Using Molecular and Visual Tools | Great Ilanga |
| * Mirko Paiardini, Emory University, ENPRC Session Chair |
| Jake D Estes, Oregon Health and Science University Decoding Tissue-Specific Dynamics of SIV Rebound in Nonhuman Primates |
| Zaza M. Ndhlovu, Africa Health Research Institute Molecular Drivers of HIV-persistence and CD8+ T Cell Dysfunction in Human Lymphoid Tissues during ART-Suppressed Subtype C Infection |
| Anna Farrell-Sherman, Fred Hutchinson Cancer Center Circulating Non-Viral Biomarkers of the Rebound Competent Reservoir |
| Thomas J. Hope, Northwestern University Short Talk: Spatial Transcriptomics Reveals Persistent Reservoirs in the Rhesus Macaque Gut are Associated with Tertiary Lymphoid Organs and Stress Response Activation |
| Candace Liu, Stanford University Short Talk: Multi-dimensional Longitudinal Spatial Profiling Reveals Dynamic ART-linked Lymphoid Tissue Remodeling in SIV Infection |
| Marta Calvet-Mirabent, Gladstone Institutes Short Talk: Active HIV Reservoir in Jejunum of ART-suppressed PWH Elicit Innate Immune Responses |
| Faiaz Shaik Abdool, Africa Health Research Institute Short Talk: Comparative Analysis of the HIV-1 Subclade C Reservoir Localization and Cellular Function in Pediatric and Adult Tonsillar Tissues |
| 9:30–9:50 AM | Coffee Break | Foyer |
| 9:50–9:55 AM | Award Recipient Acknowledgement | Great Ilanga |
| 11:30–12:30 PM | Lunch | Suites 1-5 |
| 12:00–2:30 PM | Poster Session 2 | Suites 1-5 |
| 3:00–4:30 PM | Career Roundtable | Great Ilanga |
| Azwidihwi Nthangeni Takalani, HIV Vaccines Trial Network Clinical Trial Physician (Protocol Team Leader) |
| Christine Goffinet, Liverpool School of Tropical Medicine Professor |
| Megha L Mehrotra, Gilead Sciences Associate Director of Clinical Development |
| Evelyn Yayra A Bonney, Noguchi Memorial Institute for Medical Research, University of Ghana Senior Research Fellow |
| 4:30–5:00 PM | Coffee Available | Foyer |
| 5:00–7:00 PM | Therapeutic Approaches Leading to ART-Free Control of HIV I: What’s the magic ingredient? | Great Ilanga |
| * Karsten Eichholz, Fred Hutchison Cancer Center Session Chair |
| Thomas A Rasmussen, Aarhus University Hospital Inhibiting the Anti-Apoptotic Factor, BCL-2, as an Approach to Targeting HIV Persistence |
| Rachel L. Rutishauser, University of California, San Francisco Eliciting Effective HIV-specific CD8+ T Cell Responses |
| Ming Jie Lee, Imperial College London The Use of Long-acting Broadly Neutralising Antibodies to Confer HIV Viral Control: Results from the RIO Study and Gut Sub-study |
| Dylan M Postmus, Liverpool School of Tropical Medicine Short Talk: Bryostatin-1, as Opposed to AZD5582, Impairs Cell Surface HIV-1 Env Presentation and Reduces Susceptibility to Immune Clearance during Synergistic HIV-1 Reactivation with JQ-1 |
| Merle Henderson, Imperial College London/Imperial College Healthcare NHS Trust Short Talk: The Impact of an HIV-broadly Neutralizing Antibody +/- Romidepsin at ART Start and during a Treatment Interruption on Biomarkers of Inflammation: The eCLEAR Study |
| 7:00–8:00 PM | On Own for Dinner |
| 7:30–8:30 AM | Breakfast | Individual Hotel |
| 8:30–11:30 AM | Therapeutic Approaches Leading to ART-Free Control of HIV II: Might it all be in the genes? | Great Ilanga |
| * Catherine K Koofhethile, Botswana Harvard Health Partnership Session Chair |
| Cissy Kityo, Joint Clinical Research Centre Anti-HIV CAR-T Cell Therapy |
| Mauricio Martins, University of Florida AAV-Vectored Delivery of HIV Bnabs for Tackling Pediatric HIV Infection |
| Chang Li, University of Washington In vivo HSC Gene Therapy of HIV/AIDS and SCD with Helper-Dependent Adenovirus Vectors |
| James E. Voss, The Scripps Research Institute Elicitation of Durable HIV bnAbs from Genome-edited B Cells as an Approach to Achieve a Functional Cure |
| Gerard Campos Gonzalez, IrsiCaixa Short Talk: CAR-T Cells Targeting CD4 Efficiently Eliminate HIV-1 Infected T Cells |
| Michael Moso, University of Melbourne Short Talk: CRISPR-activation for HIV Latency Reversal using Lipid Nanoparticle Delivery |
| Elena Herrera Carrillo, Amsterdam UMC Short Talk: CRISPR-Cas Therapy Towards a Cure for HIV/AIDS |
| 9:30–9:50 AM | Coffee Break | Foyer |
| 11:30–12:30 PM | Lunch | Suites 1-5 |
| 12:30–2:00 PM | Los Alamos HIV Immunology and Sequence Databases User Workshop | Great Ilanga |
| 2:30–4:30 PM | Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions | Great Ilanga |
| * Lishomwa C. Ndhlovu, Weill Cornell Medicine Session Chair |
| Mirko Paiardini, Emory University, ENPRC Immunological and Virological Characterization of Venetoclax-Induced Reservoir Reduction in SIV-Infected Rhesus Macaques |
| Henrik N Kløverpris, Africa Health Research Institute (AHRI) Targeting Gut Inflammation in HIV with GLP-1 Therapy |
| Marisa Goff, Icahn School of Medicine at Mount Sinai Combined Viral Outgrowth and Neutralization Assay to Quantify bNAb Sensitivity in the HIV-1 Latent Reservoir |
| Panagiota Zacharopoulou, University of Oxford Impact of bNAb Resistance-Associated Mutations on bNAb Treatment Outcomes in People with Early TreatedHIV in the RIO Trial |
| Rose C Kitawi, University of New South Wales Efficient Combinatorial Gene Therapy for Functional Cure of HIV Using miRshRNA Delivered RNA Sequences |
| Thembi Mdluli, Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) Initiating ART in Fiebig Stage I Limited the Development of Antibody Binding Responses Post ATI |
| 4:30–5:00 PM | Coffee Available | Foyer |
| 5:00–6:45 PM | Universal Access to Interventions that Lead to ART-Free Control of HIV: How are we going to make it happen? | Great Ilanga |
| * Damalie Nakanjako, Makerere University College of Health Sciences Session Chair |
| Steven G Deeks, University of California, San Francisco Combination Approaches Towards Eradication or Control of HIV |
| Albert Machinda, The African HIV Cure Consortium (AHCC) The African HIV Cure Consortium: Partnerships for Discovery, Development, and Roll Out of HIV Cure Initiatives in Africa |
| Patrick Mdletshe, University of KawZulu-Natal Community Engagement for HIV Cure |
| Azwidihwi Nthangeni Takalani, HIV Vaccines Trial Network Short Talk: Ensuring the Safe Implementation of Analytical Treatment Interruption in a Southern African Cohort |
| 6:45–7:00 PM | Meeting Wrap-Up: Outcomes and Future Directions (Organizers) | Great Ilanga |
| * Mike McCune, Gates Foundation |
| 7:00–8:00 PM | On Own for Dinner |
| 8:00–8:00 AM | Departure |